Therapies for B cell malignancies
US11976118B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 9, 2021 |
| Grant date | May 7, 2024 |
| Priority date | — |
| Expiry date | Aug 11, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The subject invention provides novel methods for treating B cell malignancies, such as multiple myeloma, using a combination therapy. Said treatment in accordance with the subject invention comprises the administration of a B cell regulator, e.g., a galectin molecule, to a subject suffering from a B cell malignancy, and wherein said subject received, receives, or will receive a treatment with a conventional treatment for such B cell malignancy, e.g., immunotherapy. The administration of the galectin molecule boosts the expression of B cell specific antigens e.g., SLAMF7, on MM cells, thereby increasing the sensitivity of MM cells to anti-SLAMF7 Ab and therapeutic efficacy of Elotuzumab.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.